home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550837.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
3KB
|
47 lines
Document 0837
DOCN M9550837
TI Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled
trial of treatment for either 6 or 12 months.
DT 9505
AU Perriens JH; St. Louis ME; Mukadi YB; Brown C; Prignot J; Pouthier F;
Portaels F; Willame JC; Mandala JK; Kaboto M; et al; Projet SIDA,
Kinshasa, Zaire.
SO N Engl J Med. 1995 Mar 23;332(12):779-84. Unique Identifier : AIDSLINE
MED/95166277
AB BACKGROUND. We studied the efficacy of a short-course regimen of
chemotherapy for pulmonary tuberculosis in Kinshasa, Zaire. We also
assessed whether, among patients with human immunodeficiency virus (HIV)
infection, treatment should be extended from 6 to 12 months. METHODS.
HIV-seropositive and HIV-seronegative outpatients with pulmonary
tuberculosis were treated with rifampin, isoniazid, pyrazinamide, and
ethambutol daily for two months, followed by rifampin plus isoniazid
twice weekly for four months. The HIV-positive patients who had no
evidence of tuberculosis were then randomly assigned to receive either
rifampin plus isoniazid or placebo twice weekly for a further six
months. We also followed a comparison group of HIV-seronegative patients
who received no further treatment for tuberculosis after six months.
RESULTS. After six months, 260 of 335 HIV-seropositive and 186 of 188
HIV-seronegative participants could be evaluated, and their rates of
treatment failure were similar: 3.8 and 2.7 percent, respectively. At 24
months, the HIV-seropositive patients who received extended treatment
had a relapse rate of 1.9 percent, as compared with 9 percent among the
HIV-seropositive patients who received placebo for the second 6 months
(P < 0.01). Extended treatment did not improve survival, however. Among
the HIV-seronegative patients, 5.3 percent relapsed. CONCLUSIONS. Among
HIV-seropositive patients with pulmonary tuberculosis, extending
treatment from 6 to 12 months reduces the rate of relapse but does not
improve survival. The six-month program of partly intermittent
antituberculous treatment may be an acceptable alternative when
resources are limited.
DE Adult Antibiotics, Antitubercular/*THERAPEUTIC USE AIDS-Related
Opportunistic Infections/*DRUG THERAPY/MORTALITY Female Human HIV
Seropositivity Male Prospective Studies Single-Blind Method Support,
Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Time Factors Treatment
Outcome Tuberculosis, Multidrug-Resistant Tuberculosis,
Pulmonary/*DRUG THERAPY/MORTALITY CLINICAL TRIAL JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).